Cellectis SA (CLLS) - Net Assets
Based on the latest financial reports, Cellectis SA (CLLS) has net assets worth $75.90 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($324.72 Million) and total liabilities ($248.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cellectis SA (CLLS) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $75.90 Million |
| % of Total Assets | 23.37% |
| Annual Growth Rate | 3.13% |
| 5-Year Change | -67.9% |
| 10-Year Change | -72.3% |
| Growth Volatility | 237.95 |
Cellectis SA - Net Assets Trend (2007–2025)
This chart illustrates how Cellectis SA's net assets have evolved over time, based on quarterly financial data. Also explore Cellectis SA (CLLS) total assets for the complete picture of this company's asset base.
Annual Net Assets for Cellectis SA (2007–2025)
The table below shows the annual net assets of Cellectis SA from 2007 to 2025. For live valuation and market cap data, see CLLS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $75.90 Million | -42.07% |
| 2024-12-31 | $131.03 Million | +54.71% |
| 2023-12-31 | $84.69 Million | -32.75% |
| 2022-12-31 | $125.94 Million | -46.74% |
| 2021-12-31 | $236.47 Million | -23.43% |
| 2020-12-31 | $308.85 Million | -13.12% |
| 2019-12-31 | $355.47 Million | -21.05% |
| 2018-12-31 | $450.27 Million | +57.49% |
| 2017-12-31 | $285.90 Million | +4.33% |
| 2016-12-31 | $274.05 Million | -4.92% |
| 2015-12-31 | $288.22 Million | +298.17% |
| 2014-12-31 | $72.39 Million | +988.46% |
| 2013-12-31 | $6.65 Million | -91.86% |
| 2012-12-31 | $81.69 Million | +120.64% |
| 2011-12-31 | $37.02 Million | -26.15% |
| 2010-12-31 | $50.13 Million | -31.54% |
| 2009-12-31 | $73.22 Million | +58.45% |
| 2008-12-31 | $46.21 Million | +6.13% |
| 2007-12-31 | $43.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cellectis SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33413100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.90 Million | 7.78% |
| Other Comprehensive Income | $-33.32 Million | -43.89% |
| Other Components | $437.45 Million | 576.34% |
| Total Equity | $75.90 Million | 100.00% |
Cellectis SA Competitors by Market Cap
The table below lists competitors of Cellectis SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CompX International Inc
NYSE MKT:CIX
|
$286.76 Million |
|
Incap Oyj
HE:ICP1V
|
$286.82 Million |
|
Transcontinental Inc
TO:TCL-A
|
$286.82 Million |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
$286.85 Million |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
$286.71 Million |
|
Forcecon Technology Co Ltd
TWO:3483
|
$286.67 Million |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
$286.67 Million |
|
Resolute Holdings Management, Inc.
NASDAQ:RHLD
|
$286.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellectis SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 131,033,000 to 75,901,000, a change of -55,132,000 (-42.1%).
- Net loss of 67,802,146 reduced equity.
- New share issuances of 44,000 increased equity.
- Other comprehensive income increased equity by 6,221,000.
- Other factors increased equity by 6,405,146.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-67.80 Million | -89.33% |
| Share Issuances | $44.00K | +0.06% |
| Other Comprehensive Income | $6.22 Million | +8.2% |
| Other Changes | $6.41 Million | +8.44% |
| Total Change | $- | -42.07% |
Book Value vs Market Value Analysis
This analysis compares Cellectis SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.28x to 5.22x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $3.08 | $3.95 | x |
| 2008-12-31 | $3.27 | $3.95 | x |
| 2009-12-31 | $5.18 | $3.95 | x |
| 2010-12-31 | $3.55 | $3.95 | x |
| 2011-12-31 | $2.62 | $3.95 | x |
| 2012-12-31 | $3.96 | $3.95 | x |
| 2013-12-31 | $0.34 | $3.95 | x |
| 2014-12-31 | $2.82 | $3.95 | x |
| 2015-12-31 | $8.35 | $3.95 | x |
| 2016-12-31 | $7.65 | $3.95 | x |
| 2017-12-31 | $7.48 | $3.95 | x |
| 2018-12-31 | $10.04 | $3.95 | x |
| 2019-12-31 | $7.42 | $3.95 | x |
| 2020-12-31 | $6.68 | $3.95 | x |
| 2021-12-31 | $4.94 | $3.95 | x |
| 2022-12-31 | $2.59 | $3.95 | x |
| 2023-12-31 | $1.49 | $3.95 | x |
| 2024-12-31 | $1.45 | $3.95 | x |
| 2025-12-31 | $0.76 | $3.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellectis SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -92.66%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 4.28x
- Recent ROE (-89.33%) is above the historical average (-98.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.01% | -106.22% | 0.08x | 1.24x | $-8.71 Million |
| 2008 | 0.40% | 1.25% | 0.24x | 1.32x | $-4.44 Million |
| 2009 | -7.54% | -31.87% | 0.19x | 1.25x | $-12.84 Million |
| 2010 | -21.39% | -51.11% | 0.30x | 1.38x | $-15.74 Million |
| 2011 | -83.45% | -149.05% | 0.16x | 3.56x | $-34.60 Million |
| 2012 | -37.32% | -105.89% | 0.24x | 1.46x | $-37.34 Million |
| 2013 | -1212.90% | -369.38% | 0.52x | 6.35x | $-84.97 Million |
| 2014 | 0.03% | 0.09% | 0.16x | 2.26x | $-7.37 Million |
| 2015 | -7.79% | -40.81% | 0.15x | 1.29x | $-51.28 Million |
| 2016 | -23.32% | -150.10% | 0.13x | 1.21x | $-91.32 Million |
| 2017 | -37.25% | -394.51% | 0.08x | 1.25x | $-126.05 Million |
| 2018 | -19.23% | -618.12% | 0.03x | 1.22x | $-119.62 Million |
| 2019 | -28.78% | -597.01% | 0.03x | 1.48x | $-122.20 Million |
| 2020 | -25.57% | -98.14% | 0.16x | 1.65x | $-100.95 Million |
| 2021 | -38.99% | -116.68% | 0.19x | 1.73x | $-108.41 Million |
| 2022 | -83.66% | -514.78% | 0.07x | 2.21x | $-110.48 Million |
| 2023 | -119.32% | -13385.30% | 0.00x | 3.95x | $-109.53 Million |
| 2024 | -28.05% | -88.57% | 0.11x | 2.93x | $-49.86 Million |
| 2025 | -89.33% | -92.66% | 0.23x | 4.28x | $-75.39 Million |
Industry Comparison
This section compares Cellectis SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellectis SA (CLLS) | $75.90 Million | -10.01% | 3.28x | $286.73 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more